Form 4: Avidity Biosciences CHRO Sells Shares for Tax Obligations

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, executed a non-discretionary 'sell-to-cover' transaction to satisfy tax withholding obligations related to RSU vesting.

Summary

• Teresa McCarthy, Chief Human Resources Officer of Avidity Biosciences, Inc., sold a total of 2,929 shares of common stock.
• The sales occurred on January 21, 2026, at a price of $72.45 per share.
• These transactions were non-discretionary 'sell-to-cover' sales, mandated by the company's equity incentive plans to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) on January 20, 2026.
• The sales were executed pursuant to a Rule 10b5-1 plan, indicating they were pre-scheduled and not based on new material non-public information.
• Following these transactions, Teresa McCarthy beneficially owns 113,938 shares of Avidity Biosciences common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary 'sell-to-cover' transaction for tax purposes, which is a neutral event with no direct positive or negative implications for the company's operational or financial performance.

Positives

• The transaction was non-discretionary and part of a pre-arranged Rule 10b5-1 plan, indicating routine compliance with equity compensation policies and no discretionary selling by the insider.

Negatives

• No direct negatives are identified as this is a routine tax-related transaction.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• "This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell-to-cover' transaction and does not represent a discretionary trade by the Reporting Person."
• "The Reporting Person has executed an instruction letter for the automatic sale of such 'sell-to-cover' shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1."

Industry Context

This routine insider transaction, a 'sell-to-cover' for tax obligations, is a common occurrence across publicly traded companies, particularly in the biotechnology sector where equity compensation is a significant component of executive pay. It does not reflect a change in the company's operational performance or strategic position within the industry.

Comparison to Industry Standards

• The 'sell-to-cover' mechanism for tax withholding is a standard practice in equity compensation plans across various industries, including biotechnology.
• Companies like Moderna (MRNA) and BioNTech (BNTX) also utilize similar mechanisms for their executives' RSU vestings, ensuring compliance with tax regulations while managing executive equity holdings.
• This transaction aligns with typical corporate governance practices for managing executive compensation and tax liabilities, indicating standard operational procedure rather than a unique event.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are mentioned in this Form 4 filing.

Related Party Transactions

• The transaction involves an officer of the company selling shares to cover tax obligations related to equity compensation, which is a standard arrangement under the company's equity incentive plans and not typically considered an unusual related party transaction requiring special disclosure beyond the Form 4 itself.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine, non-discretionary transaction. The sale of 2,929 shares represents a very small fraction of the company's outstanding shares.
• Employees, Customers, Suppliers, Creditors: No direct impact from this routine insider transaction.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing beyond the completion of the reported transaction.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary 'sell-to-cover' transaction by an executive to satisfy tax obligations related to RSU vesting. Such transactions are common and pre-scheduled under Rule 10b5-1 plans, indicating no new material information about the company's performance or outlook. Therefore, this specific filing does not provide a basis for changing an investment recommendation; a 'hold' stance is appropriate as the event is neutral to the company's fundamentals.

Keywords

Avidity Biosciences, RNA, Form 4, Insider Transaction, Sell-to-Cover, Teresa McCarthy, Chief Human Resources Officer, Equity Compensation, RSU Vesting, Rule 10b5-1